

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (Currently Amended): A liposome wherein a compound containing a polyalkylene glycol moiety is bonded through a thioether group to a liposome comprising lipids whose partial component has maleimidated terminal, and wherein an amount of the bonded compound is 15 to 50 40 mole% based on one mole of the maleimidated lipid contained in the liposome.

Claim 2 (Original) The liposome according to claim 1, wherein the amount of the bonded compound is 15 to 30 mole% based on one mole of the maleimidated lipids.

Claim 3 (Currently Amended): The liposome according to claim 1, which is obtained by reacting a maleimide group of the maleimidated lipid with the compound containing a polyalkylene ~~glycol~~ glycol moiety introduced with a thiol group.

Claim 4 (Previously Presented): The liposome according to claim 1, wherein the compound is bonded to a surface of the liposome.

Claim 5 (Previously Presented): The liposome according to claim 1, wherein the polyalkylene glycol is polyethylene glycol.

Claim 6 (Original): The liposome according to claim 5, wherein the compound has two polyethylene glycol groups.

Claim 7 (Original): The liposome according to claim 6, wherein the polyethylene glycol has a molecular weight of 2,000 to 7,000 daltons.

Claim 8 (Original): The liposome according to claim 6, wherein the polyethylene glycol has a molecular weight of about 5,000 daltons.

Claim 9 (Previously Presented): The liposome according to claim 1, wherein an antibody is further bonded on a surface of the liposome.

Claim 10 (Original): A liposome wherein an antibody is bonded through a thioether group to a liposome comprising lipids whose partial component has maleimidated terminal, and wherein an amount of the bonded antibody is 0.1 to 2 mole% based on one mole of the maleimidated lipids contained in the liposome.

Claim 11 (Original): The liposome according to claim 10, wherein an amount of the bonded antibody is 0.4 to 0.7 mole% based on one mole of the maleimidated lipids.

Claim 12 (Previously Presented): The liposome according to claim 10, which is obtained by reacting a liposome having a maleimide group and a sulfur-containing group deriving from the antibody to form a thioether bond.

Claim 13 (Previously Presented): The liposome according to claim 10, wherein the antibody is a GAH antibody.

Claim 14 (Previously Presented): The liposome according to claim 10, wherein the antibody is a F(ab')₂ antibody fragment.

Claim 15 (Previously Presented): The liposome according to claim 10, wherein a compound containing a polyalkylene glycol moiety is further bonded to a surface of the liposome.

Claim 16 (Original): A liposome wherein a compound containing a polyalkylene glycol moiety and an antibody are bonded through thioether groups to a liposome comprising lipids whose partial component has maleimidated terminal, and wherein an amount of the bonded compound is 15 to 30 mole% and an amount of the bonded antibody is 0.4 to 0.7 mole% based on one mole of the maleimidated lipids contained in the liposome.

Claim 17 (Original): The liposome according to claim 16, which is obtained by reacting a maleimide group of the maleimidated lipid with the compound containing a polyalkylene glycol moiety introduced with a thiol group.

Claim 18 (Previously Presented): The liposome according to claim 16, wherein the compound is bonded to a surface of the liposome.

Claim 19 (Previously Presented): The liposome according to claim 16, wherein the polyalkylene glycol is polyethylene glycol.

Claim 20 (Original): The liposome according to claim 19, wherein the compound has two polyethylene glycol groups.

Claim 21 (Original): The liposome according to claim 20, wherein the polyethylene glycol has a molecular weight of 2,000 to 7,000 daltons.

Claim 22 (Original): The liposome according to claim 20, wherein the polyethylene glycol has a molecular weight of about 5,000 daltons.

Claim 23 (Previously Presented): The liposome according to claim 16, which is a liposome obtained by reacting a liposome having a maleimide group and a sulfur-containing group deriving from the antibody to form a thioether bond.

Claim 24 (Previously Presented): The liposome according to claim 16, wherein the antibody is a GAH antibody.

Claim 25 (Previously Presented): The liposome according to claim 16, wherein the antibody is a F(ab')₂ antibody fragment.

Claim 26 (Currently Amended): A medicament composition for treatment of cancer comprising the liposome according to claim 1.

Claim 27 (Currently Amended): The medicament composition according to claim 26, wherein the cancer is stomach cancer or colon cancer.

Claim 28 (Currently Amended): A method for treatment of cancer which comprises ~~the~~ use of administering to a patient the liposome according to claim 1.

Claim 29 (New): A medicament composition for treatment of cancer comprising the liposome according to claim 10.

Claim 30 (New): The medicament composition according to claim 29, wherein the cancer is stomach cancer or colon cancer.

Claim 31 (New): A method for treatment of cancer which comprises administering to a patient the liposome according to claim 10

Claim 32 (New): A medicament composition for treatment of cancer comprising the liposome according to claim 16.

Claim 33 (New): The medicament composition according to claim 32, wherein the cancer is stomach cancer or colon cancer.

P21620.A08

Application No. 09/926,358

Claim 34 (New): A method for treatment of cancer which comprises administering to a patient the liposome according to claim 16